Studies have shown that the Novartis compound called FT720 has shown a high effectiveness for stopping exacerbations for up to 75 % of multiple sclerosis patients  after three years in an extended clinical trial. The medicine is a once a day pill that would be a more palatable alternative to the injectable therapies that are commonplace for treating MS presently.

There were hopes that the drug Rituxin might benefit multiple sclerosis patients with the primary progressive stage of the disease,  but a long term study of the therapy failed to produce a significant benefit.

The firm devoloping brochures and informational materials for a multiple sclerosis clinical trial wants your thoughts on design and suggestions on content. If you are interested please visit the post in the forum by clicking here.